Advertisement
Advertisement
U.S. Markets close in 6 hrs 5 mins
Advertisement
Advertisement
Advertisement
Advertisement

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.91-0.09 (-1.50%)
As of 09:51AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.00
Open5.99
Bid5.93 x 1300
Ask6.00 x 2900
Day's Range5.91 - 5.99
52 Week Range5.77 - 14.00
Volume596
Avg. Volume28,238
Market Cap132.518M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CENTOGENE Reports Third Quarter 2021 Financial Results

    Second Consecutive Quarter of Core Business Growth, Phasing Out COVID-19 Testing and Restructuring Organization for Core Rare Disease BusinessCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the third quarter ended September 30, 2021, and provided a recent business update. Ex

  • GlobeNewswire

    CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

    CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter ended September 30, 2021, on Wednesday, November 24, 2021, and will host a conference call and webcast to discuss these results at 2 p.m. CET / 8 a.m. ET that day. Participants may register i

  • GlobeNewswire

    CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

    Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search for a TreatmentCAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today that it has expanded its partnership with Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a l

Advertisement
Advertisement